86-0512-86669213
SuZhou Teligene ,Ltd. was established in 2011 and settled in Suzhou Bio-Nano Park, with a registered capital of 360 million yuan. Dr. Zhang Dawei, who has studied in the United States and served as the chief scientist of Amgen, one of the world's largest biopharmaceutical companies for a long time Founded.
More
Suzhou Taolue's wholly-owned subsidiary Jiangsu Maidu Pharmaceutical Research and Development Co., Ltd. obtains the production license for anti-tumor solid preparation drugs
Taoluo's subsidiary, Shanghai Taoluo Biotechnology Co., Ltd. was established
Suzhou Taolue's wholly-owned subsidiary, Jiangsu Maidu Pharmaceutical Research and Development Co., Ltd. invested 120 million yuan to build G118, a standard factory building of about 11,000 square meters, for the production and supporting projects of targeted drug oral solid preparations
Suzhou Taoluo's wholly-owned subsidiary, Jiangsu Medo Pharmaceutical Research and Development Co., Ltd., was approved as a foreign expert studio in Jiangsu Province
Taolue Subsidiary Suzhou Junde Biotechnology Co., Ltd. was established
Taolue subsidiary Hangzhou Derun Yucheng Biotechnology Co., Ltd. was established
Maidu Company settled in the national technology business incubator of China Medical City, through internal operation and outsourcing cooperation, to create a complete set of infrastructure and R&D conditions for new drug R&D and registration application.
Suzhou Taolue Biotechnology Co., Ltd. was established, located in the Bio-Nano Park of Suzhou Industrial Park
Maidu company is located in the national new drug creation base of China Medical City, Taizhou, and begins formal operations
Signed a contract with Jiangsu Suzhong Pharmaceutical Group Co., Ltd. for the research and development of a new EGFR-KTI targeted anti-tumor drug
Jiangsu Maidu Drug Research and Development Co., Ltd. was established
We are committed to seeking innovative treatment methods in the field of oncology, discovering and developing molecules with new mechanisms of action to improve the treatment effect of patients when their medical needs are not met.
Energy、Energize、Execution、E-communication
Patientfirst
